摘要
目的探究利拉鲁肽与二甲双胍联合治疗对糖尿病合并非酒精性脂肪性肝病患者疗效、肝脏脂肪含量及ANGPTL4和CTRP12表达的影响。方法选取96例我院于2021年2月~2023年8月期间收治的2型糖尿病合并非酒精性脂肪肝患者,随机分为两组,即对照组(48例)和治疗组(48例)。比较两组患者临床疗效;检测血糖指标、脂代谢指标及肝脏功能指标;比较两组患者血清中ANGPTL4和CTRP12水平及肝脏脂肪含量;评价两组患者不良反应发生情况。结果治疗组较对照组患者临床疗效升高(P<0.05)。和治疗前相比,治疗后两组患者FBG、HbA1c、HOMA-IR指标、血清中ALT、AST、TC、TG、LDL-C、HDL-C指标、ANGPTL4、CTRP12水平及肝脏脂肪含量均降低,FINS增加(P<0.05);和治疗后对照组相比,治疗组患者FBG、HbA1c、HOMA-IR指标、血清中ALT、AST、TC、TG、LDL-C、HDL-C指标、ANGPTL4、CTRP12水平及肝脏脂肪含量均降低,FINS增加(P<0.05)。对照组不良反应(恶心呕吐、头晕、腹泻、低血糖)发生情况和治疗组相比无明显差异(P>0.05)。结论利拉鲁肽与二甲双胍联合治疗可降低2型糖尿病合并非酒精性脂肪肝患者血糖、血脂及肝脏功能,抑制血清中ANGPTL4、CTRP12水平和肝脏脂肪含量,值得临床推广应用。
Objective:To investigate the effect of rilalutide combined with metformin on the efficacy,liver fat content,and the expression of ANGPTL4 and CTRP12 in patients with diabetes complicated with nonalcoholic fatty liver disease.Methods:A total of 96 patients with type 2 diabetes complicated with nonalcoholic fatty liver were selected from the Department of Endocrinology of our hospital from February 2021 to August 2023.They were randomly divided into the control group(48 cases)and the treatment group(48 cases).Compare the clinical efficacy of two groups of patients;Detecting blood glucose indicators,lipid metabolism indicators,and liver function indicators;Compare the levels of ANGPTL4 and CTRP12 in the serum and liver fat content between two groups of patients;Evaluate the occurrence of adverse reactions in two groups of patients.Results:The clinical efficacy of the treatment group was higher than that of the control group(P<0.05).Compared with before treatment,after treatment,FBG,HbA1c,HOMA-IR indicators,serum ALT,AST,TC,TG,LDL-C,HDL-C indicators,ANGPTL4,CTRP12 levels,and liver fat content in both groups of patients decreased,while FINS increased(P<0.05);Compared with the control group after treatment,the FBG,HbA1c,HOMA-IR indicators,serum ALT,AST,TC,TG,LDL-C,HDL-C indicators,ANGPTL4,CTRP12 levels,and liver fat content in the treatment group were all reduced,while FINS increased(P<0.05).There was no significant difference in the incidence of adverse reactions(nausea,vomiting,dizziness,diarrhea,hypoglycemia)between the control group and the treatment group(P>0.05).Conclusion:Lilalutide combined with metformin can reduce blood glucose,blood lipid and liver function in type 2 diabetes patients with nonalcoholic fatty liver disease,inhibit the levels of ANGPTL4,CTRP12 in serum and liver fat content,and has high safety,which is worthy of clinical application.
作者
王晓燕
张晓敏
魏雪
王丁
Wang Xiaoyan;Zhang Xiaomin;Wei Xue;WANG Ding(Physical Examination Center of the Third Hospital of Shijiazhuang,Shijiazhuang 050000,China;Department of Pharmacy,The Third Hospital of Shijiazhuang,Shijiazhuang 050000,China;Department of Pharmacy,Shijiazhuang People's Hospital,Shijiazhuang 050000,China)
出处
《生命科学仪器》
2023年第6期209-212,共4页
Life Science Instruments
